Abstract
Background and Aims: Recent evidence has shown that cardiac hypertrophy can remodel the extracellular matrix and increase the expression of chondroitin sulfate proteoglycans (CSPG) in both rats and humans. Previously, we characterized anti-atherogenic properties of a novel anti-CSPG antibody (chP3R99 Ab) that is able to display an idiotypic vaccination effect in several species. In this study we sought to assess the impact of chP3R99 in the development of cardiac hypertrophy associated with the metabolic syndrome.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
